{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:19:06Z","timestamp":1787548746143,"version":"build-2736575974"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bibliometric methods were employed to visually examine the global trends and progression of PPAR\u03b3 in the breast with the aim of clarifying the evolution of significant academic contributions, collaborative networks, foundational disciplines, and key terms. A comprehensive search was conducted on publications related to PPAR\u03b3 in breast cancer research using the Web of Science Core Collection database (WOSCC) and PubMed. The reference types for the WOSCC database were restricted to articles and reviews published in English, whereas PubMed focused on randomized controlled trials (RCTs). Data visualization and analysis were conducted using bibliometric tools, including CiteSpace, VOSviewer, Bibliometrix, and Scimago Graphica. Sensitivity analysis for non-deterministic indicators and bias risk assessment of RCTs were also conducted. A total of 1,391 publications and 3 RCTs were included in this study. The annual growth rate of publications in this field was 3.54%. The primary contributing countries were the United States, China, Japan, and Italy. The top three authors with the highest academic contributions were Catalano, Stefania, Bonofiglio, Daniela, and Ando, Sebastiano, which were also the most frequently cited authors. The most frequent keywords were PPAR\u03b3, breast cancer, apoptosis, and expression. This study provides the first bibliometric overview of PPAR\u03b3 research in breast cancer, highlighting a continuous increase in scholarly output, with major contributions from Europe, the Americas, and Asia. The discipline has gradually evolved from initial basic and preclinical studies to exploring the complex regulatory system of the \u201ccancer - metabolism - immunity\u201d interaction network. Currently, the effectiveness of conventional PPAR\u03b3 agonists in clinical trials is still limited, highlighting the urgent need and potential for the clinical development of highly selective PPAR\u03b3 modulators. This review aims to deepen our understanding of the role of PPAR\u03b3 in breast cancer, support the translation of related research into clinical practice, and offer a theoretical basis and directional guidance for future advancements in this field.<\/jats:p>","DOI":"10.3389\/fonc.2026.1908399","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:23:41Z","timestamp":1787545421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global pattern and evolution of PPAR\u03b3 in breast cancer: a 25-Year bibliometric and visualized knowledge map analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaotian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, Baoji Central Hospital","place":["Baoji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Baoji Central Hospital","place":["Baoji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Baoji Central Hospital","place":["Baoji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Baoji Central Hospital","place":["Baoji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"She","sequence":"additional","affiliation":[{"name":"Department of Breast, Baoji Central Hospital","place":["Baoji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2583870","article-title":"The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model","volume":"28","author":"Kasle","year":"2025","journal-title":"J Med Econ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01208-7","article-title":"Oestrogen changes at menopause: insights into obesity-associated breast risk and outcomes","volume":"22","author":"Sho","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18212","article-title":"SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation","volume":"28","author":"He","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.39063","article-title":"Macrophage colony-stimulating factor mediates the recruitment of macrophages in triple negative breast cancer","volume":"15","author":"Lu","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.92125","article-title":"Reprogramming of lipid metabolism mediates crosstalk, remodeling, and intervention of microenvironment components in breast cancer","volume":"20","author":"Wang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111236","article-title":"ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives - Endorsed by ASTRO","volume":"214","author":"Zamagni","year":"2026","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.003","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42\/AFT-05\/PrE0109\/BIG-14-13)","volume":"37","author":"Mayer","year":"2026","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123787","article-title":"A TNBC-targeting nano-radiosensitizer reverses radioresistance by synergizing GSH scavenging with dual inhibition of Trop2 and lncRNA MNX1-AS1","volume":"327","author":"Yang","year":"2026","journal-title":"Biomaterials"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02412","article-title":"Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin in early-stage triple-negative breast cancer (RJBC 1501): a randomized phase III trial","volume":"44","author":"Chen","year":"2026","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.111377","article-title":"Targeted axillary dissection in breast cancer: current evidence and ongoing trials","volume":"52","author":"Loi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18546-5","article-title":"Omission of axillary lymph node dissection in patients with pT0-2 ER+\/HER2- breast cancer with 3-5 positive lymph nodes undergoing adjuvant systemic therapy and radiation does not impact overall survival: a National Cancer Database analysis","volume":"33","author":"Tang","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000004002","article-title":"Surgical management of breast cancer: a review","volume":"87","author":"Hirachan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/prs.0000000000012325","article-title":"Anticancer agents and their impact on breast reconstruction: a guide for plastic surgeons based on systematic review and expert consensus","volume":"157","author":"Zona","year":"2026","journal-title":"Plast Reconstr Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.176","article-title":"Signaling pathways in the regulation of cancer stem cells and associated targeted therapy","volume":"3","author":"Manni","year":"2022","journal-title":"MedComm (2020)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13020-025-01310-y","article-title":"Unraveling the potential mechanisms of Xiaochaihu decoction alleviates metabolic associated fatty liver disease (MAFLD) by integrated transcriptomics, metabolomics, and network pharmacology","volume":"21","author":"Zhong","year":"2026","journal-title":"Chin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/cancers13092153","article-title":"PPARs and tumor microenvironment: the emerging roles of the metabolic master regulators in tumor stromal-epithelial crosstalk and carcinogenesis","volume":"13","author":"Cheng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118264","article-title":"Structural and functional insights into PPAR-\u03b3: review of its potential and drug design innovations for the development of antidiabetic agents","volume":"302","author":"Gupta","year":"2026","journal-title":"Eur J Med Chem"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1080\/15376516.2025.2537889","article-title":"Enhanced anti-cancer efficacy of sorafenib and pioglitazone via VEGF inhibition in DMBA-induced breast cancer model","volume":"35","author":"Soni","year":"2025","journal-title":"Toxicol Mech Methods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.3390\/ijms262311389","article-title":"Investigating the role of peroxisomes in regulating breast cancer stem cell mechanisms","volume":"26","author":"Simsek","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2015.08.004","article-title":"Omega-3 DHA- and EPA-dopamine conjugates induce PPAR\u03b3-dependent breast cancer cell death through autophagy and apoptosis","volume":"1850","author":"Rovito","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12032-024-02363-z","article-title":"Dual function of activated PPAR\u03b3 by ligands on tumor growth and immunotherapy","volume":"41","author":"Chen","year":"2024","journal-title":"Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91155","article-title":"Research hotspots and trends of endoplasmic reticulum stress in obesity from 2014 to 2024: a CiteSpace visualization analysis","volume":"17","author":"Zhang","year":"2025","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(00)80047-7","article-title":"Terminal differentiation of human breast cancer through PPAR gamma","volume":"1","author":"Mueller","year":"1998","journal-title":"Mol Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice","volume":"95","author":"Elstner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/2030","article-title":"Differentiation and reversal of Malignant changes in colon cancer through PPARgamma","volume":"4","author":"Sarraf","year":"1998","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor","volume":"94","author":"Tontonoz","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1023\/a:1024038127156","article-title":"Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study","volume":"79","author":"Burstein","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"B32","article-title":"Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo","volume":"58","author":"Kubota","year":"1998","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1167804","article-title":"PPAR gamma signaling exacerbates mammary gland tumor development","volume":"18","author":"Saez","year":"2004","journal-title":"Genes Dev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1947","article-title":"Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers","volume":"13","author":"Yee","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-016-2317-y","article-title":"Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial","volume":"16","author":"Kopp","year":"2016","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13045-018-0670-9","article-title":"Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)","volume":"11","author":"Liang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12906-019-2715-1","article-title":"The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-\u03b3 and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial","volume":"19","author":"Pirouzpanah","year":"2019","journal-title":"BMC Complement Altern Med"},{"key":"B39","article-title":"Treatment of early stage breast cancer","volume":"55","year":"1991","journal-title":"Conn Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202506162","article-title":"Reevaluating the roles of PPARs and nuclear receptors in human peroxisome biology","volume":"224","author":"Mast","year":"2025","journal-title":"J Cell Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41421-022-00388-0","article-title":"PPAR\u03b3 phase separates with RXR\u03b1 at PPREs to regulate target gene expression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002997117","article-title":"Blocking PPAR\u03b3 interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression","volume":"117","author":"Yang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308435","article-title":"In silico discovery of stapled peptide inhibitor targeting the Nur77-PPAR\u03b3 interaction and its anti-breast-cancer efficacy","volume":"11","author":"Bian","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501387287250611095023","article-title":"Lipidomics in breast cancer: decoding metabolic reprogramming and unlocking therapeutic opportunities","volume":"26","author":"Singhai","year":"2025","journal-title":"Curr Drug Targets"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102059","article-title":"Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: role of PPAR\u03b3 in cell apoptosis","volume":"32","author":"Alqahtani","year":"2024","journal-title":"Saudi Pharm J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.3390\/ijms21249721","article-title":"Natural and synthetic PPAR\u03b3 ligands in tumor microenvironment: a new potential strategy against breast cancer","volume":"21","author":"Augimeri","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10495-025-02232-8","article-title":"LncRNA PVT1 drives macrophage polarization and triple-negative breast cancer progression via PPAR\u03b3-mediated transcriptional activation","volume":"31","author":"Zhang","year":"2026","journal-title":"Apoptosis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-36","article-title":"COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ","volume":"8","author":"Kulkarni","year":"2008","journal-title":"BMC Cancer"},{"key":"B49","article-title":"CK20 expression enhances the invasiveness of tamoxifen-resistant MCF-7 cells","volume":"32","author":"Min","year":"2012","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-015-0347-8","article-title":"Opposing roles for mammary epithelial-specific PPAR\u03b3 signaling and activation during breast tumour progression","volume":"14","author":"Apostoli","year":"2015","journal-title":"Mol Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"10535","DOI":"10.3390\/ijms231810535","article-title":"TRIB3 modulates PPAR\u03b3-mediated growth inhibition by interfering with the MLL complex in breast cancer cells","volume":"23","author":"Hern\u00e1ndez-Quiles","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303774120","article-title":"Loss of PPAR\u03b3 activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity","volume":"120","author":"Caruso","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116645","article-title":"Tetrastigma polysaccharide reprogramming of tumor-associated macrophages via PPAR\u03b3 signaling pathway to play antitumor activity in breast cancer","volume":"314","author":"Liu","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11371","article-title":"Ligand-activated PPAR\u03b3 downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression","volume":"7","author":"Rovito","year":"2016","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03492-z","article-title":"PPAR\u03b3 acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding","volume":"44","author":"Tian","year":"2025","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1186\/s12885-024-12931-1","article-title":"Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis","volume":"24","author":"Hu","year":"2024","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2559.2005.02056.x","article-title":"PPARgamma expression in breast cancer: clinical value and correlation with ERbeta","volume":"46","author":"Papadaki","year":"2005","journal-title":"Histopathology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401191R","article-title":"The anti-tumor effects of cosmosiin through regulating AhR\/CYP1A1-PPAR\u03b3 in breast cancer","volume":"38","author":"Wang","year":"2024","journal-title":"FASEB J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cells13171506","article-title":"Class effect unveiled: PPAR\u03b3 agonists and MEK inhibitors in cancer cell differentiation","volume":"13","author":"Ben-Yishay","year":"2024","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.3390\/jcm10204641","article-title":"Troglitazone-induced PRODH\/POX-dependent apoptosis occurs in the absence of estradiol or ER\u03b2 in ER-negative breast cancer cells","volume":"10","author":"Lewoniewska","year":"2021","journal-title":"J Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.01.025","article-title":"INT131: a selective modulator of PPAR gamma","volume":"386","author":"Motani","year":"2009","journal-title":"J Mol Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4481354","article-title":"PPARG: a promising therapeutic target in breast cancer and regulation by natural drugs","volume":"2023","author":"Li","year":"2023","journal-title":"PPAR Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.99275","article-title":"PPARG activation of fatty acid metabolism drives resistance to anti-HER2 therapies in HER2-positive breast cancer","volume":"21","author":"Xiong","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"22988","DOI":"10.1038\/s41598-024-71962-7","article-title":"Cystathionine-\u03b3-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPAR\u03b3\/ACSL1\/STAT3 signalling pathway in oestrogen receptor-positive breast cancer","volume":"14","author":"Fu","year":"2024","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12202","article-title":"Increasing doxorubicin activity against breast cancer cells using PPAR\u03b3-ligands and by exploiting circadian rhythms","volume":"169","author":"Arif","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s11701-026-03798-4","article-title":"A bibliometric analysis of the robotic revolution in prostate cancer surgery: evolution, hotspots, and future directions","volume":"20","author":"Zhang","year":"2026","journal-title":"J Robotic Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:23:42Z","timestamp":1787545422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":66,"alternative-id":["10.3389\/fonc.2026.1908399"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1908399","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1908399"}}